Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2255-2261

  Faure, Sebastien ^a   Oudart, Nicole ^a   Javellaud, James ^a   Fournier, Albert ^b   Warnock, David G ^c   Achard, Jean Michel ^a,d  

^a UNIVERSITY OF LIMOGES   (France)

^b University of Amiens   (France)

^c University of Alabama at Birmingham   (United States)

^d Faculte de Medecine   (France)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Erythropoietin; Stroke

Indexed keywords

OLMESARTAN; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY LIGATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GERBIL; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RECOGNITION; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE;

EID: 33750246621     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249704.34607.4c     Document Type: Article

References (26)

1. Birmingham K. Future of neuroprotective drugs in doubt [editorial]. Nat Med 2002; 8:5.
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
3. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl) 2001; 101:271-276.
4. Bernaudin M, Bellail A, Marti HH, Yvon A, Vivien D, Duchatelle I, et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000; 30:271-278.
5. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000; 15:225-229.
6. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6:484-494.
7. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004; 19:195-206.
8. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001; 98:4044-4049.
9. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
10. Fagan SC, Kozak A, Hill WD, Pollock D, Xu L, Johnson M, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24:535-539.
11. Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, et al. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134:225-231.
12. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24:467-474.
13. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-1703.
14. Fernandez LA, Caride VJ, Stromberg C, Naveri L, Wicke JD. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994; 24:937-940.
15. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1 behavioral data. Behav Brain Res 1988; 31:47-59.
16. Morris RGM. Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11:47-60.
17. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004; 101:14907-14912.
18. Fernandez L, Spencer D, Kaczmar T. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986; 17:82-85.
19. Kaliszewski C, Fernandez L, Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil: role of endogenous angiotensin II. J Cerebral Blood Flow Metab 1988; 8:149-154.
20. Dalmay F, Mazouz H, Allard J, Pesteil F, Achard JM, Fournier A. Non AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst 2001; 2:103-106.
21. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19:617-619.
22. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.
23. Shibasaki Y, Mori Y, Tsutumi Y, Masaki H, Sakamoto K, Murasawa S, et al. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 1999; 51:83-91.
24. Albiston AL, Fernando R, Ye S, Peck GR, Chai SY. Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms. Behav. Brain Res 2004; 154:239-243.
25. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276:48623-48626.
26. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 2003; 86:344-350.